Decoding Rejection: CareDx & 10x Genomics Target Transplant Crisis

BRISBANE, CA – January 07, 2026 – In a significant move to reshape the future of transplant medicine, precision diagnostics leader CareDx has announced a strategic collaboration with life science technology firm 10x Genomics. The partnership launches ImmuneScape™, an ambitious research initiative designed to create a detailed map of the human immune system's response to organ transplantation, aiming to solve one of the field's most persistent challenges: organ rejection.

For decades, the success of a life-saving transplant has been shadowed by the constant threat of the recipient's body attacking the new organ. This collaboration combines CareDx's deep clinical expertise in transplantation with 10x Genomics' revolutionary single-cell and spatial biology platforms, promising to unlock biological secrets that have remained hidden from conventional diagnostic tools.

Beyond the Biopsy: A New Paradigm for Patient Monitoring

The current gold standard for detecting organ rejection is the tissue biopsy—an invasive, painful, and costly procedure that carries inherent risks of bleeding, infection, and damage to the very organ it aims to protect. Patients often undergo numerous biopsies in the years following their transplant. Furthermore, the interpretation of biopsy results can be subjective, with different pathologists sometimes reaching different conclusions from the same tissue sample. This diagnostic uncertainty complicates treatment decisions.

While less invasive methods like blood tests measuring donor-derived cell-free DNA (dd-cfDNA) have emerged as valuable monitoring tools, they have limitations. They often signal that damage is already underway but may not specify the type or severity of the rejection, such as differentiating between T-cell mediated rejection (TCMR) and the more challenging antibody-mediated rejection (AMR). The ImmuneScape initiative aims to move beyond detecting damage to proactively understanding the cellular drivers of rejection before it becomes irreversible.

"Despite extensive prior research, our understanding of the biology of transplant rejection remains incomplete," said Serge Saxonov, Co-founder and CEO of 10x Genomics, in a statement. The goal is to create a new paradigm where clinicians can understand rejection not as a single event, but as a complex, dynamic process that can be mapped and, ultimately, managed with unprecedented precision.

A Cellular Blueprint of Rejection

The ImmuneScape program will leverage two of 10x Genomics' flagship platforms, Chromium Flex and Xenium, to generate multiomic data—a layered, comprehensive view of biological activity. This approach provides two critical pieces of information: what is happening at the single-cell level and where it is happening within the organ tissue.

The Chromium Flex platform provides the 'what' by analyzing the gene expression of thousands of individual cells from a biopsy sample. This allows researchers to identify every type of immune cell involved in the rejection process—from aggressive T-cells to antibody-producing B-cells—and understand their specific activation states. It can reveal the rare but potent cell populations that may be driving the attack.

Complementing this, the Xenium platform provides the 'where'. This spatial biology technology maps gene expression directly within the context of the tissue. Researchers can visualize the precise locations of immune cells, see how they organize into attack formations, and understand how they interact with the organ's cells, particularly in cases of microvascular inflammation (MVI), a key feature of AMR. This spatial context is something traditional biopsies and non-invasive blood tests simply cannot provide.

Critically, both platforms are compatible with Formalin-Fixed Paraffin-Embedded (FFPE) samples, the standard method for preserving clinical biopsy tissues. This compatibility is a game-changer, as it unlocks vast archives of existing patient samples, enabling large-scale studies that can correlate these deep biological maps with years of known clinical outcomes.

A Strategic Alliance to Redefine Diagnostics

For CareDx, which bills itself as 'The Transplant Company™', this collaboration is a calculated strategic move to solidify its leadership in a transplant diagnostics market projected to be worth billions of dollars within the next decade. The initiative builds directly upon the company's existing portfolio, including its recently introduced HistoMap™ Kidney, a gene expression classifier that already aims to refine rejection subtyping.

ImmuneScape extends that effort, aiming to generate insights that will fuel a next generation of diagnostic products. By understanding the intricate immune architecture of rejection, CareDx hopes to develop tests that can not only detect rejection earlier but also predict a patient's response to specific therapies, such as emerging anti-CD38 treatments for AMR. This paves the way for true personalized medicine in transplantation.

"This collaboration marks a meaningful step in advancing precision transplant care," stated John Hanna, President & CEO of CareDx. "By uniting CareDx’s clinical and diagnostic expertise with 10x Genomics’ transcriptomics technologies, we’re building upon a robust scientific foundation to drive future organ-health innovation across our diagnostic pipeline. Through ImmuneScape we aim to generate insights that translate transplant biology into high-value patient impact."

The Long Road from Data to Better Outcomes

While the promise of ImmuneScape is immense, the path from a research initiative to a widely available clinical test is long and arduous. Translating these complex multiomic insights into a robust, reliable, and regulatory-approved diagnostic will require years of work and significant investment. The new tools will need to undergo rigorous clinical validation to prove they improve patient outcomes, and securing reimbursement from insurers will be another critical hurdle.

However, the potential payoff for patients is transformative. A deeper understanding of rejection could lead to diagnostics that enable doctors to tailor immunosuppression regimens for each individual, minimizing toxic side effects while maximizing graft survival. It could give patients and their families peace of mind, replacing the anxiety of invasive procedures with the clarity of precise molecular data.

By examining immune activity at a resolution previously thought impossible, the partnership between CareDx and 10x Genomics opens a new window into the cellular and molecular signatures of rejection. Charting this unknown territory is the first step toward transforming complex biological data into tangible improvements in the lives of transplant patients worldwide.